Roles and Regulation of BCL-xL in Hematological Malignancies
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Members of the Bcl-2 family are proteins that play an essential role in the regulation of apoptosis, a crucial process in development and normal physiology in multicellular organisms. The essential mechanism of this family of proteins is given by the role of pro-survival proteins, which inhibit apoptosis by their direct binding with their counterpart, the effector proteins of apoptosis. This family of proteins was named after the typical member Bcl-2, which was named for its discovery and abnormal expression in B-cell lymphomas. Subsequently, the structure of one of its members BCL-xL was described, which allowed one to understand much of the molecular mechanism of this family. Due to its role of BCL-xL in the regulation of cell survival and proliferation, it has been of great interest in its study. Due to this, it is important to research its role regarding the development and progression of human malignancies, especially in hematologic malignancies. Due to its variation in expression in cancer, it has been suggested that BCL-xL can or cannot play a role in cancer depending on the cellular or tissue context. This review discusses recent advances in its transcriptional regulation of BCL-xL, as well as the advances regarding the activities of BCL-xL in hematological malignancies, its possible role as a biomarker, and its possible clinical relevance in these malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, Src inhibitors oppose activating phosphorylation of the STAT3 transcription factor, which inhibits the transcription of multiple genes that encode protein implicated in AML survival and proliferation e.g., MCL-1,18 BCL-xL,52 and c-MYC.55”
From Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia (2025) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
miRBase: from microRNA sequences to function
Kozomara, A., Birgaoanu, M., & Griffiths-Jones, S. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1141 · Cited by 4,843
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219 · cited 1×
“Due to its participation in the regulation of apoptosis, a process whose evasion is directly related to the generation of malignant processes [7], alteration in the expression of the members of the BCL-2 family has been reported as fundamental in the generation and promotion of cancer [8].”
BackgroundMicroRNA profiling: approaches and considerations
Pritchard, C. C., Cheng, H. H., & Tewari, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3198 · Cited by 1,765
McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKearn, J. P., & Korsmeyer, S. J. (1989) · Cell · doi:10.1016/0092-8674(89)90174-8 · Cited by 1,213 · cited 4×
““Storz Lymphoma” [30], in which it can be observed that, compared to tonsils used as a control, the expression of BCL-xL in cutaneous follicular lymphoma (CFL), DLBCL and marginal zone B cell lymphoma is increased (Figure 3B).”
BackgroundInfluentialZhu, Y., Doornebal, E. J., Pirtskhalava, T., Giorgadze, N., Wentworth, M., Fuhrmann-Stroissnigg, H., Niedernhofer, L. J., Robbins, P. D., Tchkonia, T., & Kirkland, J. L. (2017) · Aging · doi:10.18632/aging.101202 · Cited by 757
MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression
Ivanovska, I., Ball, A. S., Diaz, R. L., Magnus, J. F., Kibukawa, M., Schelter, J. M., Kobayashi, S. V., Lim, L., Burchard, J., Jackson, A. L., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01977-07 · Cited by 561
Expression of bcl-xL can confer a multidrug resistance phenotype
Minn, A., Rudin, C., Boise, L., & Thompson, C. (1995) · Blood · doi:10.1182/blood.v86.5.1903.bloodjournal8651903 · Cited by 415 · cited 2×
“That is why the BCL-2 family of proteins, and specifically BCL-xL, has high importance as therapeutic targets for the treatment of cancer given their function as inhibitors of apoptosis and resistance to therapy [5].”
Background
Research works printed but not linked: 87
- Morales-Martinez, M., and Vega, M.I. (2021). Participation of different miRNAs in the regulation of YY1: Their role in pathogenesis, chemoresistance, and therapeutic implication in hematologic malignancies. YY1 Control. Pathog. Drug Resist. Cancer., 171–198. · DOI
- Xerri, 1996, Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas, Br. J. Haematol., 92, 900, 10.1046/j.1365-2141.1996.423958.x · DOI
- Shangary, 2003, Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family, Leukemia, 17, 1470, 10.1038/sj.leu.2403029 · DOI
- Chapman, 2011, Initial genome sequencing and analysis of multiple myeloma, Nature, 471, 467, 10.1038/nature09837 · DOI · Paper page
- Youle, 2008, The BCL-2 protein family: Opposing activities that mediate cell death, Nat. Rev. Mol. Cell Biol., 9, 47, 10.1038/nrm2308 · DOI · Paper page
- Hanahan, 2011, Hallmarks of Cancer: The Next Generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
- Boise, 1993, bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death, Cell, 74, 597, 10.1016/0092-8674(93)90508-N · DOI · Paper page
- Tsujimoto, 2000, Bcl-2 family: Life-or-death switch, FEBS Lett., 466, 6, 10.1016/S0014-5793(99)01761-5 · DOI · Paper page
- Nakamura, 2016, Bcl-xL Is Essential for the Survival and Function of Differentiated Neurons in the Cortex That Control Complex Behaviors, J. Neurosci., 36, 5448, 10.1523/JNEUROSCI.4247-15.2016 · DOI · Paper page
- Borrás, C., Mas-Bargues, C., Román-Domínguez, A., Sanz-Ros, J., Gimeno-Mallench, L., Inglés, M., Gambini, J., and Viña, J. (2020). BCL-xL, a Mitochondrial Protein Involved in Successful Aging: From C. elegans to Human Centenarians. Int. J. Mol. Sci., 21. · DOI
- Muchmore, 1996, X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death, Nature, 381, 335, 10.1038/381335a0 · DOI · Paper page
- Trisciuoglio, D., Tupone, M.G., Desideri, M., Di Martile, M., Gabellini, C., Buglioni, S., Pallocca, M., Alessandrini, G., D’Aguanno, S., and Del Bufalo, D. (2017). BCL-XL overexpression promotes tumor progression-associated properties. Cell Death Dis., 8. · DOI
- Hager, J.H., Ulanet, D.B., Hennighausen, L., and Hanahan, D. (2009). Genetic Ablation of Bcl-x Attenuates Invasiveness without Affecting Apoptosis or Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Cancer. PLoS ONE, 4. · DOI
- Choi, S., Chen, Z., Tang, L.H., Fang, Y., Shin, S.J., Panarelli, N.C., Chen, Y.-T., Li, Y., Jiang, X., and Du, Y.-C.N. (2016). Bcl-xL promotes metastasis independent of its anti-apoptotic activity. Nat. Commun., 7. · DOI
- Cho, 2017, Targeting the Overexpressed YY1 in Cancer Inhibits EMT and Metastasis, Crit. Rev. Oncog., 22, 49, 10.1615/CritRevOncog.2017020473 · DOI
- Su, R.-J., Baylink, D.J., Neises, A., Kiroyan, J.B., Meng, X., Payne, K.J., Tschudy-Seney, B., Duan, Y., Appleby, N., and Kearns-Jonker, M. (2013). Efficient Generation of Integration-Free iPS Cells from Human Adult Peripheral Blood Using BCL-XL Together with Yamanaka Factors. PLoS ONE, 8. · DOI
- Gabellini, 2008, Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma, J. Neurochem., 107, 871, 10.1111/j.1471-4159.2008.05661.x · DOI
- Gabellini, 2017, Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model, Int. J. Cancer, 142, 584, 10.1002/ijc.31075 · DOI
- Zhang, 2013, An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1, Br. J. Cancer, 108, 1870, 10.1038/bjc.2013.152 · doi:10.1038/bjc.2013.152
- Martens, U. (2018). Venetoclax: Targeting BCL2 in Hematological Cancers. Small Molecules in Hematology. Recent Results in Cancer Research, Springer.
- Yalniz, 2019, Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies, Drugs, 79, 1287, 10.1007/s40265-019-01163-4 · DOI
- Li, 2007, Targeting Antiapoptotic Bcl-2 Family Members with Cell-Permeable BH3 Peptides Induces Apoptosis Signaling, Death in Head, Neck Squamous Cell Carcinoma Cells, Neoplasia, 9, 801, 10.1593/neo.07394 · DOI
- Mateos-Chávez, A.A., Muñoz-López, P., Becerra-Báez, E.I., Flores-Martínez, L.F., Prada-Gracia, D., Moreno-Vargas, L.M., Baay-Guzmán, G.J., Juárez-Hernández, U., Chávez-Munguía, B., and Cabrera-Muñóz, L. (2019). Live Attenuated Salmonella enterica Expressing and Releasing Cell-Permeable Bax BH3 Peptide Through the MisL Autotransporter System Elicits Antitumor Activity in a Murine Xenograft Model of Human B Non-hodgkin’s Lymphoma. Front. Immunol., 10. · DOI
- Rhodes, 2004, ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform, Neoplasia, 6, 533, 10.1016/S1476-5586(04)80047-2 · DOI · Paper page
- Basso, 2005, Reverse engineering of regulatory networks in human B cells, Nat. Genet., 37, 382, 10.1038/ng1532 · DOI · Paper page
- Storz, 2003, Gene Expression Profiles of Cutaneous B Cell Lymphoma, J. Investig. Dermatol., 120, 865, 10.1046/j.1523-1747.2003.12142.x · doi:10.1046/j.1523-1747.2003.12142.x
- Huang, 2002, The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile, Blood, 99, 2285, 10.1182/blood.V99.7.2285 · DOI · Paper page
- Kang, 2009, Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy, Clin. Cancer Res., 15, 1126, 10.1158/1078-0432.CCR-08-0144 · DOI · Paper page
- Baritaki, 2011, Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis, Cell Cycle, 10, 2792, 10.4161/cc.10.16.16952 · DOI
- Compagno, 2009, Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma, Nature, 459, 717, 10.1038/nature07968 · DOI · Paper page
- Perri, 2014, BCL-xL/MCL-1 inhibition and RARγ antagonism work cooperatively in human HL60 leukemia cells, Exp. Cell Res., 327, 183, 10.1016/j.yexcr.2014.07.024 · DOI
- Mirjolet, 2000, Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status, Br. J. Cancer, 83, 1380, 10.1054/bjoc.2000.1455 · DOI
- Kogan, 2001, Bcl-2 Cooperates with Promyelocytic Leukemia Retinoic Acid Receptor α Chimeric Protein (Pmlrarα) to Block Neutrophil Differentiation and Initiate Acute Leukemia, J. Exp. Med., 193, 531, 10.1084/jem.193.4.531 · DOI · Paper page
- Zou, J., Li, P., Lu, F., Liu, N., Dai, J., Ye, J., Qu, X., Sun, X., Ma, D., and Park, J. (2013). Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J. Hematol. Oncol., 6. · DOI
- Zhou, 1997, [Relationship between bcl-X(L) expression and sensitivity to chemotherapy in acute myeloid leukemic cells], Zhonghua Xue Ye Xue Za Zhi, 18, 584
- Souers, 2013, ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat. Med., 19, 202, 10.1038/nm.3048 · DOI · Paper page
- Poeta, 2008, Deregulation of the Mitochondrial Apoptotic Machinery and Development of Molecular Targeted Drugs in Acute Myeloid Leukemia, Curr. Cancer Drug Targets, 8, 207, 10.2174/156800908784293640 · DOI
- Rahmani, 2015, Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation, Haematologica, 100, 1553, 10.3324/haematol.2015.130351 · DOI
- Andersson, 2007, Microarray-based classification of a consecutive series of 121 childhood acute leukemias: Prediction of leukemic and genetic subtype as well as of minimal residual disease status, Leukemia, 21, 1198, 10.1038/sj.leu.2404688 · DOI · Paper page
- Tu, 1998, BCL-X expression in multiple myeloma: Possible indicator of chemoresistance, Cancer Res., 58, 256
- Punnoose, 2016, Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models, Mol. Cancer Ther., 15, 1132, 10.1158/1535-7163.MCT-15-0730 · DOI · Paper page
- Badros, 2005, Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination with Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients, J. Clin. Oncol., 23, 4089, 10.1200/JCO.2005.14.381 · DOI
- Lernoux, M., Schnekenburger, M., Dicato, M., and Diederich, M. (2021). Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors. Biochem. Pharmacol., 188. · DOI
- Kline, 2007, ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells, Leukemia, 21, 1549, 10.1038/sj.leu.2404719 · DOI · Paper page
- Ackler, 2010, The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo, Cancer Chemother. Pharmacol., 66, 869, 10.1007/s00280-009-1232-1 · DOI
- Vaxman, 2018, Venetoclax for the treatment of multiple myeloma, Expert Rev. Hematol., 11, 915, 10.1080/17474086.2018.1548931 · DOI
- Chen, 2009, BCL-xL Is a Target Gene Regulated by Hypoxia-inducible Factor-1α, J. Biol. Chem., 284, 10004, 10.1074/jbc.M805997200 · DOI · Paper page
- Packham, 1998, Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies, Genes Dev., 12, 2475, 10.1101/gad.12.16.2475 · DOI
- Puthier, 1999, Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells, Br. J. Haematol., 107, 392, 10.1046/j.1365-2141.1999.01705.x · DOI · Paper page
- Grad, 2000, Regulation of Bcl-xL: A little bit of this and a little bit of STAT, Curr. Opin. Oncol., 12, 543, 10.1097/00001622-200011000-00006 · DOI · Paper page
- Licata, 2020, SIGNOR 2.0, the SIGnaling Network Open Resource 2.0: 2019 update, Nucleic Acids Res., 48, D504
- Dreos, 2017, The eukaryotic promoter database in its 30th year: Focus on non-vertebrate organisms, Nucleic Acids Res., 45, D51, 10.1093/nar/gkw1069 · DOI · Paper page
- Baritaki, 2013, Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer, Nitric Oxide, 29, 17, 10.1016/j.niox.2012.12.001 · DOI
- Valencia, 2019, Regulation of Krüppel-Like Factor 4 (KLF4) expression through the transcription factor Yin-Yang 1 (YY1) in non-Hodgkin B-cell lymphoma, Oncotarget, 10, 2173, 10.18632/oncotarget.26745 · DOI
- Wu, 2013, Transcription Factor YY1 Contributes to Tumor Growth by Stabilizing Hypoxia Factor HIF-1α in a p53-Independent Manner, Cancer Res., 73, 1787, 10.1158/0008-5472.CAN-12-0366 · DOI
- Morales-Martinez, M., Vega, G.G., Neri, N., Nambo, M.J., Alvarado, I., Cuadra, I., Duran-Padilla, M.A., Huerta-Yepez, S., and Vega, M.I. (2020). MicroRNA-7 Regulates Migration and Chemoresistance in Non-Hodgkin Lymphoma Cells Through Regulation of KLF4 and YY1. Front. Oncol., 10. · doi:10.3389/fonc.2020.588893
- Xiong, 2011, MicroRNA-7 Inhibits the Growth of Human Non-Small Cell Lung Cancer A549 Cells through Targeting BCL-2, Int. J. Biol. Sci., 7, 805, 10.7150/ijbs.7.805 · DOI · Paper page
- Ambros, 2003, MicroRNA Pathways in Flies and Worms: Growth, Death, Fat, Stress, and Timing, Cell, 113, 673, 10.1016/S0092-8674(03)00428-8 · DOI · Paper page
- Bartel, 2004, MicroRNAs: Genomics, Biogenesis, Mechanism, and Function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
- Calin, 2002, Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. USA, 99, 15524, 10.1073/pnas.242606799 · DOI · Paper page
- Lawrie, 2013, MicroRNAs in hematological malignancies, Blood Rev., 27, 143, 10.1016/j.blre.2013.04.002 · DOI
- Yendamuri, 2009, The role of microRNA in human leukemia: A review, Leukemia, 23, 1257, 10.1038/leu.2008.382 · DOI
- 2015, Circulating microRNA expression profile in B-cell acute lymphoblastic leukemia, Cancer Biomark., 15, 299, 10.3233/CBM-150465 · DOI
- Bonavida, B. (2021). YY1 in the Control of the Pathogenesis and Drug Resistance of Cancer, Elsevier.
- Agnelli, 2009, A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect, Genes Chromosom. Cancer, 48, 603, 10.1002/gcc.20668 · DOI · Paper page
- Zhan, 2006, The molecular classification of multiple myeloma, Blood, 108, 2020, 10.1182/blood-2005-11-013458 · DOI · Paper page
- Raab, 2009, Targeting PKC: A novel role for beta-catenin in ER stress and apoptotic signaling, Blood, 113, 1513, 10.1182/blood-2008-05-157040 · DOI
- Neri, 2008, The oral protein-kinase Cβinhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines, Leuk. Lymphoma, 49, 1374, 10.1080/10428190802078289 · DOI
- Rao, 2010, MicroRNA-34a Perturbs B Lymphocyte Development by Repressing the Forkhead Box Transcription Factor Foxp1, Immunity, 33, 48, 10.1016/j.immuni.2010.06.013 · DOI · Paper page
- Wentzel, 2005, c-Myc-regulated microRNAs modulate E2F1 expression, Nature, 435, 839, 10.1038/nature03677 · DOI · Paper page
- Vega, 2012, Hypoxia inducible factor-1? induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL, Leuk. Lymphoma, 54, 1048
- Witten, 2019, miR-155 as a novel clinical target for hematological malignancies, Carcinogenesis, 41, 2, 10.1093/carcin/bgz183 · DOI
- Zhou, 2010, High-risk myeloma is associated with global elevation of miRNAs and overexpression ofEIF2C2/AGO2, Proc. Natl. Acad. Sci. USA, 107, 7904, 10.1073/pnas.0908441107 · DOI · Paper page
- Agnelli, L., Bisognin, A., Todoerti, K., Manzoni, M., Taiana, E., Galletti, S., Cutrona, G., Gaffo, E., Bortoluzzi, S., and Neri, A. (2019). Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing. Blood Cancer J., 9. · DOI
- Calin, 2017, Cancer Hallmarks and MicroRNAs: The Therapeutic Connection, Adv. Cancer Res., 135, 119, 10.1016/bs.acr.2017.06.002 · DOI · Paper page
- Al-Harbi, S., Choudhary, G.S., Ebron, J.S., Hill, B.T., Vivekanathan, N., Ting, A.H., Radivoyevitch, T., Smith, M.R., Shukla, G.C., and Almasan, A. (2015). miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies. Mol. Cancer, 14. · DOI
- Shen, 2019, MicroRNA-125a regulates proliferation and apoptosis of acute myeloid leukemia through targeting NF-κB pathway, Eur. Rev. Med. Pharmacol. Sci., 23, 3594
- Gong, 2012, MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R, Oncogene, 32, 3071, 10.1038/onc.2012.318 · DOI · Paper page
- Farrugia, M.K., Sharma, S.B., Lin, C.-C., McLaughlin, S., Vanderbilt, D.B., Ammer, A.G., Salkeni, M., Stoilov, P., Agazie, Y.M., and Creighton, C.J. (2015). Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer. Cell Death Dis., 6. · DOI
- Gao, J., Gu, J., Pan, X., Gan, X., Ju, Z., Zhang, S., Xiaojie, G., Lu, L., and Wang, X. (2019). Blockade of miR-142-3p promotes anti-apoptotic and suppressive function by inducing KDM6A-mediated H3K27me3 demethylation in induced regulatory T cells. Cell Death Dis., 10. · DOI
- Ji, 2013, MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1, Bone, 56, 220, 10.1016/j.bone.2013.05.020 · DOI
- Shimizu, 2010, The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma, J. Hepatol., 52, 698, 10.1016/j.jhep.2009.12.024 · DOI · Paper page
- Rosenwald, 2002, The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma, N. Engl. J. Med., 346, 1937, 10.1056/NEJMoa012914 · DOI · Paper page
- Lenz, 2008, Stromal Gene Signatures in Large-B-Cell Lymphomas, N. Engl. J. Med., 359, 2313, 10.1056/NEJMoa0802885 · DOI · Paper page
- Heuser, 2005, Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia, Haematologica, 90, 1484
- Bullinger, 2004, Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia, N. Engl. J. Med., 350, 1605, 10.1056/NEJMoa031046 · DOI · Paper page
- Yang, 2011, Prognostic significance of Bcl-xL gene expression in human colorectal cancer, Acta Histochem., 113, 810, 10.1016/j.acthis.2011.01.002 · DOI
Cited by
BCL-2 protein family: attractive targets for cancer therapy
Kaloni, D., Diepstraten, S. T., Strasser, A., & Kelly, G. L. (2023) · Apoptosis · doi:10.1007/s10495-022-01780-7 · Cited by 500
Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia
Hu, X., Li, L., Nkwocha, J., Kmieciak, M., Shang, S., Cowart, L. A., Yue, Y., Horimoto, K., Hawkridge, A., Rijal, A., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02125-x · Cited by 15
Metadata
- Authors
- Morales-Martínez, M., & Vega, M. I.
- Affiliations
- Molecular Signal Pathway in Cancer Laboratory, UIMEO, Oncology Hospital, Siglo XXI National Medical Center, IMSS, México City 06720, Mexico
- ORCID
- Vega, Mario I.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-02-16
- Volume
- 23
- Issue
- 4
- Pages
- 2193
- ISSN
- 1422-0067
- Cited by
- 39
- References
- 7
- Language
- en
- Funders
- National Institutes of Health (RO1CA111448, RO1CA211562, R21CA168491, RO1CA217820.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Roles and Regulation of BCL-xL in Hematological Malignancies. https://app.cochat.ai/papers/10.3390/ijms23042193
- The paper
- Morales-Martínez, M., & Vega, M. I. (2022). Roles and Regulation of BCL-xL in Hematological Malignancies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms23042193
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.